国际指数编制公司MSCI(摩根士丹利资本国际)最新公布的2026年2月全球小盘股指数季度调整结果,劲方医药(2595.HK)成功入选,成为本次调整中唯一纳入该指数的Biotech企业。值得关注的是,这家聚焦RAS赛道的创新药企于2025年9月19日才登陆港交所主板,上市时间不足半年便获国际资本认可,彰显其核心竞争力与发展潜力。据悉,本次指数调整将于2月27日收盘后正式生效,纳入后劲方医药将获得被动...
Source Link国际指数编制公司MSCI(摩根士丹利资本国际)最新公布的2026年2月全球小盘股指数季度调整结果,劲方医药(2595.HK)成功入选,成为本次调整中唯一纳入该指数的Biotech企业。值得关注的是,这家聚焦RAS赛道的创新药企于2025年9月19日才登陆港交所主板,上市时间不足半年便获国际资本认可,彰显其核心竞争力与发展潜力。据悉,本次指数调整将于2月27日收盘后正式生效,纳入后劲方医药将获得被动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.